Benufutamab

贝奴妥单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBenufutamab
Drug Alias NameHexaBody-DR5/DR5iDD-004GEN-1029Hx-DR5-01Hx-DR5-05
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonists
TargetsTumor necrosis factor receptor superfamily member 10B
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIdd Biotech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenmab A/S
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsStomach Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A